当前位置:首页 - 行情中心 - 东宝生物(300239) - 财务分析 - 现金流量表

东宝生物

(300239)

  

流通市值:30.96亿  总市值:31.17亿
流通股本:5.90亿   总股本:5.94亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金164,105,643.42668,879,098.4489,226,887.66342,473,382.7
  收到的税费返还204,814.455,389,635.263,132,961.813,132,961.81
  收到其他与经营活动有关的现金482,985.8716,490,205.8613,254,958.023,209,237.6
  经营活动现金流入小计164,793,443.74690,758,939.52505,614,807.49348,815,582.11
  购买商品、接受劳务支付的现金91,284,635.14349,225,621.94277,542,636.41180,860,276.63
  支付给职工以及为职工支付的现金43,063,430.43163,134,062.76120,249,35380,142,356.89
  支付的各项税费3,990,542.8153,508,901.5234,066,074.3929,073,959.33
  支付其他与经营活动有关的现金5,521,561.9518,966,240.6812,339,049.978,446,484.61
  经营活动现金流出小计143,860,170.33584,834,826.9444,197,113.77298,523,077.46
  经营活动产生的现金流量净额20,933,273.41105,924,112.6261,417,693.7250,292,504.65
二、投资活动产生的现金流量:
  处置固定资产、无形资产和其他长期资产收回的现金净额-151,315118,103.6791,555
  收到的其他与投资活动有关的现金946,277,106.183,965,883,879.492,909,427,989.541,951,938,996.77
  投资活动现金流入小计946,277,106.183,966,035,194.492,909,546,093.211,952,030,551.77
  购建固定资产、无形资产和其他长期资产支付的现金47,160,545.1379,272,782.846,923,643.0628,827,962.09
  支付其他与投资活动有关的现金944,080,3303,960,000,0002,905,000,0001,949,000,000
  投资活动现金流出小计991,240,875.134,039,272,782.82,951,923,643.061,977,827,962.09
  投资活动产生的现金流量净额-44,963,768.95-73,237,588.31-42,377,549.85-25,797,410.32
三、筹资活动产生的现金流量:
  取得借款收到的现金-54,400,00054,400,00054,400,000
  收到其他与筹资活动有关的现金-113,104.02113,104.02113,104.02
  筹资活动现金流入平衡项目-000
  筹资活动现金流入小计-54,513,104.0254,513,104.0254,513,104.02
  偿还债务支付的现金-52,096,70049,326,70025,686,700
  分配股利、利润或偿付利息支付的现金219,716.2518,278,322.0917,963,157.7915,415,096.64
  支付其他与筹资活动有关的现金-56,114,846.3656,114,846.3656,114,846.36
  筹资活动现金流出小计219,716.25126,489,868.45123,404,704.1597,216,643
  筹资活动产生的现金流量净额-219,716.25-71,976,764.43-68,891,600.13-42,703,538.98
四、汇率变动对现金及现金等价物的影响-4,320.24-50,573.03-50,162.06-57,817.13
五、现金及现金等价物净增加额-24,254,532.03-39,340,813.15-49,901,618.32-18,266,261.78
  加:期初现金及现金等价物余额458,774,068.33498,114,881.48498,114,881.48498,114,881.48
  期末现金及现金等价物余额434,519,536.3458,774,068.33448,213,263.16479,848,619.7
补充资料:
  净利润-54,335,408.98-36,967,123.15
  资产减值准备-16,003,053.1-2,791,532.1
  固定资产和投资性房地产折旧-89,594,869.54-43,312,666.55
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-89,594,869.54-43,312,666.55
  无形资产摊销-7,664,276.58-3,947,242.74
  长期待摊费用摊销-1,101,108.68-627,993.11
  处置固定资产、无形资产和其他长期资产的损失-93,367.15-310,270.68
  固定资产报废损失-273,368.91-4,006.27
  财务费用-2,811,818.65-1,121,054.55
  投资损失-2,861,860.37-1,566,045.78
  递延所得税-191,508.36-1,638,629.23
  其中:递延所得税资产减少--5,180,434.47--1,277,685.07
    递延所得税负债增加-5,371,942.83-2,916,314.3
  存货的减少--59,982,098.27--40,271,039.06
  经营性应收项目的减少-71,755,603.95-99,887,085.84
  经营性应付项目的增加--82,520,985.3--100,528,958.26
  其他-1,740,951.92--1,081,148.03
  现金的期末余额-458,774,068.33-479,848,619.7
  减:现金的期初余额-498,114,881.48-498,114,881.48
  现金及现金等价物的净增加额--39,340,813.15--18,266,261.78
公告日期2026-04-242026-03-302025-10-292025-08-29
审计意见(境内)标准无保留意见
TOP↑